表紙
市場調查報告書

雙特異性抗體全球市場:市場機會、醫藥品銷售、臨床試驗相關考察 (2026年)

Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026

出版商 KuicK Research 商品編碼 923628
出版日期 內容資訊 英文 510 Pages
商品交期: 最快1-2個工作天內
價格
雙特異性抗體全球市場:市場機會、醫藥品銷售、臨床試驗相關考察 (2026年) Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026
出版日期: 2020年02月03日內容資訊: 英文 510 Pages
簡介

雙特異性抗體自2015年上市以來在全球銷售穩定成長,至2019年的CAGR為118%。不僅是達成短期銷售目標,也正穩步建立身為次世代抗體療法的地位。

本報告研究全球雙特異性抗體市場,彙整雙特異性抗體概要、診斷和治療主要效果、目前開發中和臨床試驗中的PIPELINE產品概要、主要市場推動和阻礙因素、整體市場規模趨勢展望,並提供按類別的市場規模和價格趨勢展望、未來市場機會等情報。

第1章 雙特異性單株抗體:簡介

  • 單株抗體概要
  • 雙特異性單株抗體概要
  • 相較單特異性單株抗體之雙特異性抗體優點

第2章 雙特異性抗體工程和開發

  • 類似IgG的雙特異性抗體
    • Quadroma(Hybrid Hydromas)技術
    • KIH (Knobs Into Holes) 技術
    • CrossMab技術
    • 雙可變域免疫球蛋白技術
  • 小型雙特異性抗體
    • 雙特異性雙鏈抗體
    • BiTEs (雙特異性T細胞銜接抗體)

第3章 雙特異性抗體作用機制

  • 三功能性抗體:Catumaxomab(Removab (R))
  • Blinatumomab

第4章 雙特異性抗體 (BsMAb):診斷和治療領域的應用

  • 細菌性和病毒性傳染性疾病診斷的BsMAb
  • 癌症診斷用BsMAb
  • 信號通路阻斷的BsAbs
  • 以腫瘤血管生成為標靶的BsAbs
  • 效應化合物標靶的特異傳達
  • 雙特異性抗體和基因治療

第5章 全球雙特異性抗體市場未來展望

  • 目前市場情勢
  • 雙特異性抗體可用性
    • Catumaxomab(Removab)
    • Blinatumomab
    • Emicizumab
    • Duligotumab
    • SAR 156597

第6章 核准的雙特異性抗體:劑量與價格分析

  • Blincyto
  • Hemlibra

第7章 核准的雙特異性抗體:銷售分析

  • Blincyto
  • Hemlibra

第8章 雙特異性抗體:臨床PIPELINE概要

  • 按Phase
  • 按國家/區域
  • 按企業
  • 按症狀
  • 罕見疾病的雙特異性抗體

第9章 全球雙特異性抗體臨床PIPELINE:按企業、症狀、Phase

  • 研究
  • 臨床前
  • Phase-I
  • Phase-I/II
  • Phase-II
  • Phase-II/III
  • Phase-III

第10章 已上市雙特異性抗體:臨床見解

  • Blinatumomab (Amgen)
  • Emicizumab (中外製藥)

第11章 全球雙特異性抗體市場:市場動態

  • 有利的市場參數
  • 商業化挑戰

第12章 全球雙特異性抗體市場:未來展望

第13章 競爭環境

  • Ablynx
  • Adimab
  • Affimed Therapeutics
  • Amgen
  • AstraZeneca (MedImmune)
  • 中外製藥
  • Eli Lilly
  • EMD Serono
  • Emergent BioSolutions
  • Genentech
  • Genmab
  • Immunomedics
  • Jounce Therapeutics
  • MacroGenics
  • Merus
  • Neovii Biotech
  • NovImmune SA
  • OncoMed Pharmaceuticals
  • Pieris
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
目錄

"Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights:

  • Global Bispecific Antibody Market Opportunity: > US$ 10 Billion
  • Global Bispecific Antibody Market Growth: 118% CAGR (2015 -2019)
  • Global Bispecific Antibody Market Growth In 2019: 280% (> US$ 1.5 Billion)
  • Global Bispecific Antibody Pipeline: 333 Drug
  • Commercially Available Bispecific Antibodies: 2 (Blincyto & Hemlibra)
  • Hemlibra Sales & Market Share 2019: > US$ 1.4 Billion & > 80%

“Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026” provides comprehensive insight on clinical and non-clinical factors that are driving the global bispecific antibodies market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the sales insight on two (Blincyto & Hemlibra) commercially available bispecific antibodies with their regional level revenue, market share and the clinical profile.

"Since Commercially Launch In 2015, The Global Bispecific Antibody Market Has Witnessed Growth of 118% CAGR Till 2019"

The availability of the bispecific antibodies in the market and the revenue generated by the drugs in short span of four years (since commercialization in 2015) clearly depicts the current dominant trends followed by its characterization as a next generation of antibody therapy. The number of the investigational agents under preclinical and clinical trials all around the globe adds as a major key component for the establishment of the antibody therapy as a one stop treatment for all the disease.

Pharmaceutical companies involved in the development of these promising bispecific antibodies molecules strongly believe that their products are superior to first generation nonspecific antibody products. No doubt they are adamant to their viewpoint that bispecific antibodies will be more potent against disease targets, which includes combating more than one aspect of the disease simultaneously, better and cheaper production with least side effects. The molecules are also said to have the potential of dealing with multiple disease with a single agent making them more important.

“Structural Diversity Among The Antibodies Are Opening A Wide Plethora For The Novel Bispecific Antibody Agents, And Thus Providing A Great Opportunity For Establishing A Superior Market In The Future.”

Bispecific antibodies are not only being developed for the oncological use but also the non oncological which includes rejection of organ transplants, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, allergies and ophthalmic problems making their usage area wide enough to make ample of monetary gains in the near future. Their vitality if approved can also make them a great tool in the diagnostics tests detect and monitor infectious agents like HIV, the cause of AIDS, or the influenza virus causing pandemic flu and for identifying diseases released by biological weapons such as smallpox and anthrax. In addition, monoclonal antibodies have also helped in checks for salmonella and bacteria that cause food poisoning. The global opportunity value of the bispecific antibody market is estimated to be approximately US$ 10 billion per year, which is expected to be achieved in next five year timeframe.

Table of Contents

1. Introduction to Bispecific Monoclonal Antibody

  • 1.1. Overview of Monoclonal Antibody
  • 1.2. Overview of Bispecific Monoclonal Antibody
  • 1.3. Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

2. The Engineering & Development of Bispecific Antibodies

  • 2.1. Bispecific Antibodies Similar to IgG
    • 2.1.1. Quadroma (Hybrid Hydromas) Approach
    • 2.1.2. “Knobs Into Holes” Approach
    • 2.1.3. CrossMab Approach
    • 2.1.4. Dual-Variable-Domain Immunoglobulin Approach
  • 2.2. Small Bispecific Antibodies
    • 2.2.1. Bispecific Diabodies
    • 2.2.2. Bispecific T-Cell Engager Antibodies (BiTEs)

3. Mechanism Of Action Of Bispecific Antibody

  • 3.1. Trifunctional Antibody: Catumaxomab (Removab®)
  • 3.2. Blinatumomab

4. Applications of Bispecific Antibodies in Diagnostic & Treatment

  • 4.1. BsMAb for Diagnosis of Bacterial & Viral Infectious Diseases
  • 4.2. BsMAb for Cancer Diagnostic
  • 4.3. BsAbs Blocking Signaling Pathways
  • 4.4. BsAbs Targeting Tumor Angiogenesis
  • 4.5. Specific Delivery of Effector Compounds to Targets
  • 4.6. Bispecific Antibodies & Gene Therapy

5. Global Bispecific Antibody Market Outlook

  • 5.1. Current Market Scenario
  • 5.2. Availability of Bispecific Antibodies
    • 5.2.1. Catumaxomab (Removab)
    • 5.2.2. Blinatumomab
    • 5.2.3. Emicizumab
    • 5.2.4. Duligotumab
    • 5.2.5. SAR 156597

6. Approved Bispecific Antibody Dosage & Price Analysis

  • 6.1. Blincyto
  • 6.2. Hemlibra

7. Approved Bispecific Antibody Sales Analysis

  • 7.1. Blincyto
  • 7.2. Hemlibra

8. Global Bispecific Antibodies Clinical Pipeline Overview

  • 8.1. By Phase
  • 8.2. By Country/Region
  • 8.3. By Company
  • 8.4. By Indication
  • 8.5. Orphan Designated Bispecific Antibodies

9. Global Bispecific Antibodies Clinical Pipeline By Company, Indication & Phase

  • 9.1. Research
  • 9.2. Preclinical
  • 9.3. Phase-I
  • 9.4. Phase-I/II
  • 9.5. Phase-II
  • 9.6. Phase-II/III
  • 9.7. Phase-III

10. Marketed Bispecific Antibodies Clinical Insight

  • 10.1. Blinatumomab - Amgen
  • 10.2. Emicizumab - Chugai Pharmaceutical

11. Global Bispecific Antibody Market Dynamics

  • 11.1. Favorable Market Parameters
  • 11.2. Commercialization Challenges

12. Global Bispecific Antibody Market Future Prospects

13. Competitive Landscape

  • 13.1. Ablynx
  • 13.2. Adimab
  • 13.3. Affimed Therapeutics
  • 13.4. Amgen
  • 13.5. AstraZeneca (MedImmune)
  • 13.6. Chugai Pharmaceutical
  • 13.7. Eli Lilly
  • 13.8. EMD Serono
  • 13.9. Emergent BioSolutions
  • 13.10. Genentech
  • 13.11. Genmab
  • 13.12. Immunomedics
  • 13.13. Jounce Therapeutics
  • 13.14. MacroGenics
  • 13.15. Merus
  • 13.16. Neovii Biotech
  • 13.17. NovImmune SA
  • 13.18. OncoMed Pharmaceuticals
  • 13.19. Pieris
  • 13.20. Regeneron Pharmaceuticals
  • 13.21. Roche
  • 13.22. Sanofi

List of Figures

  • Figure 1-1: Advantages of Bispecific Antibodies
  • Figure 2-1: Types of Approaches to Form IgG like Bispecific Antibodies
  • Figure 2-2: Method of Formation of Hybrid Hybridoma
  • Figure 2-3: Limitations of Hybrid Hybridoma
  • Figure 2-4: Steps involved in “Knobs into Holes” Approach
  • Figure 2-5: Three different CrossMabs are Obtained by Three Different Modifications
  • Figure 2-6: Method for formation of Dual-Variable-Domain Immunoglobulin
  • Figure 2-7: Advantages of Dual Variable Domain Immunoglobulin approach
  • Figure 2-8: Types of Bispecific Antibodies
  • Figure 3-1: Mechanism of Action of Bispecific Monoclonal Antibody
  • Figure 3-2: Mechanism of Action of Catumaxomab
  • Figure 3-3: Mechanism of Action of Blinatumomab
  • Figure 4-1: Applications of Bispecific Antibodies
  • Figure 5-1: Global - Bispecific Antibody Market Size (US$ Million), 2015 - 2019
  • Figure 5-2: US v/s ROW - Bispecific Antibody Market Share (%) , 2018
  • Figure 5-3: US v/s ROW - Bispecific Antibody Market Share (%) , 2019
  • Figure 5-4: Global - Bispecific Antibody Market Size (US$ Million) by Products (Blincyto & Hemlibra) , 2018 & 2019
  • Figure 5-5: Global - Bispecific Antibody Market Share(%) by Products (Blincyto & Hemlibra) , 2018
  • Figure 5-6: Global - Bispecific Antibody Market Share(%) by Products (Blincyto & Hemlibra) , 2019
  • Figure 5-7: Global - Bispecific Antibody Quarterly Sales (US$ Million), by Products (Blincyto & Hemlibra), 2019
  • Figure 6-1: Blincyto - Recommended Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, December'2019
  • Figure 6-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days) , December'2019
  • Figure 6-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-Cell Precursor ALL (US$), December'2019
  • Figure 6-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, December'2019
  • Figure 6-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), December'2019
  • Figure 6-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), December'2019
  • Figure 6-7: Blincyto - Cost of Different Treatment Phases & Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), December'2019
  • Figure 6-8: Hemlibra - Cost for Single Unit of 30mcg & 150mcg Subcutaneous Injection (US$), December'2019
  • Figure 6-9: Hemlibra - Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/Kg/Week), December'2019
  • Figure 6-10: Hemlibra - Average Monthly & Annual Cost for Treatment of Hemophilia A (US$), December'2019
  • Figure 7-1: Blincyto - Sales Value (US$ Million), 2015 - 2019
  • Figure 7-2: US - Blincyto Sales Value (US$ Million), 2016 - 2019
  • Figure 7-3: Global ( Ex USA) - Blincyto Sales Value (US$ Million), 2016 - 2019
  • Figure 7-4: Blincyto - Quarterly Sales Value (US$ Million), 2018
  • Figure 7-5: Blincyto - Quarterly Sales Value (US$ Million), 2019
  • Figure 7-6: Blincyto - US v/s Rest of World Share in Sales Value (%), 2018
  • Figure 7-7: Blincyto - US v/s Rest of World Share in Sales Value (%), 2019
  • Figure 7-8: Hemlibra - Sales Value by Countries (US$ Million), 2019
  • Figure 7-9: Hemlibra - Sales Value by Countries (US$ Million), 2018
  • Figure 7-10: Hemlibra - Sales Value Share by Countries (%), 2018
  • Figure 7-11: Global - Hemlibra Quarterly Sales Value (US$ Million), 2018
  • Figure 7-12: Global - Hemlibra Half Yearly Sales Value (US$ Million), 2018 & 2019
  • Figure 7-13: Hemlibra - Half Year Sales Value by Countries (US$ Million), 2018 & 2019
  • Figure 7-14: Hemlibra - Quarterly Sales Value (US$ Million), 2019
  • Figure 7-15: Hemlibra - 9 Months Sales Value by Countries (US$ Million), 2019
  • Figure 7-16: Hemlibra - 9 Month Sales Value Share by countries (%), 2019
  • Figure 8-1: Global - Bispecific Antibodies Clinical Pipeline by Phase (%), 2020 till 2026
  • Figure 8-2: Global - Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2020 till 2026
  • Figure 8-3: Global - Bispecific Antibodies in Clinical Pipeline by Country (Numbers), 2020 till 2026
  • Figure 8-4: Global - Bispecific Antibodies in Clinical Pipeline by Company (Numbers), 2020 till 2026
  • Figure 8-5: Global - Bispecific Antibodies in Clinical Pipeline by Indication (Numbers), 2020 till 2026
  • Figure 8-6: Global - Bispecific Antibodies in Clinical Pipeline by Orphan Status (Numbers), 2020 till 2026
  • Figure 11-1: Favorable Market Parameters Global Bispecific Antibody Market
  • Figure 11-2: Commercialization Challenges for Bispecific Antibody
  • Figure 12-1: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2020 - 2026
  • Figure 13-1: Ablynx - Clinical Pipeline
  • Figure 13-2: Affimed Therapeutics - Clinical Pipeline
  • Figure 13-3: Amgen - Clinical Pipeline
  • Figure 13-4: EMD Serono - Clinical Pipeline
  • Figure 13-5: Emergent Bioscience - Clinical Pipeline
  • Figure 13-6: Genmab - Clinical Pipeline
  • Figure 13-7: Jounce Therapeutics - Clinical Pipeline
  • Figure 13-8: MacroGenics - Clinical Pipeline
  • Figure 13-9: Merus - Clinical Pipeline
  • Figure 13-10: Novimmune - Clinical Pipeline
  • Figure 13-11: OncoMed - Clinical Pipeline
  • Figure 13-12: Pieris Pharmaceuticals - Clinical Pipeline
  • Figure 13-13: Roche - Clinical Pipeline

List of Tables

  • Table 2-1: List of Bispecific Antibodies Formed by Hybrid Hybridoma Method
  • Table 2-2: List of Bispecific Antibodies Formed by DART
  • Table 2-3: List of Bispecific Antibodies Formed by BiTE Method
  • Table 2-4: List of Other BiTEs
  • Table 4-1: Bispecific Antibodies Targeting Cancer